NASDAQ:ARRY - Array Biopharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $23.13 +1.09 (+4.95 %) (As of 02/15/2019 04:00 PM ET)Previous Close$23.13Today's Range$22.06 - $23.1952-Week Range$12.56 - $23.19Volume4.74 million shsAverage Volume4.12 million shsMarket Capitalization$5.05 billionP/E Ratio-31.68Dividend YieldN/ABeta1.37 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases in North America, Europe, and the Asia Pacific. It provides BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF mutation. The company's lead clinical programs include encorafenib and binimetinib that are investigated in approximately 30 clinical trials for various solid tumor indications, including a Phase III trial in BRAF-mutant colorectal cancer. Its product pipeline also includes ipatasertib, an AKT inhibitor that is in Phase III trial to treat prostate or breast cancers; selumetinib, a MEK inhibitor for cancer; larotrectinib, a PanTrk inhibitor that is in a Phase II/registration clinical trial for cancer; tucatinib, a HER2 inhibitor for breast cancer, which is in Phase II/registration trial; and ARRY-797 that is in Phase III clinical trial for Lamin A/C-related dilated cardiomyopathy. In addition, the company is developing varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric cancer; ARRY-382, a CSF1R inhibitor that is in Phase II clinical trial to treat cancer; motolimod/VTX-2337, a Toll-like receptor that is in Phase II clinical trial for cancer; and prexasertib/LY2606368, a CHK-1 inhibitor, which is in multiple Phase I or II clinical trials for cancer. Further, its drug candidates in Phase I clinical trials include GDC-0575, a CHK-1 inhibitor for cancer; LOXO-292, a RET inhibitor to treat cancer; and LOXO-195, a Trk inhibitor for cancer. Additionally, its drug candidates include Ganovo/danoprevir, a protease inhibitor for hepatitis C virus. The company was founded in 1998 and is headquartered in Boulder, Colorado. Receive ARRY News and Ratings via Email Sign-up to receive the latest news and ratings for ARRY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ARRY Previous Symbol CUSIP04269X10 Webwww.arraybiopharma.com Phone303-381-6600Debt Debt-to-Equity Ratio0.46 Current Ratio6.31 Quick Ratio6.31Price-To-Earnings Trailing P/E Ratio-31.68 Forward P/E Ratio-38.55 P/E GrowthN/A Sales & Book Value Annual Sales$173.77 million Price / Sales29.05 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book17.66Profitability EPS (Most Recent Fiscal Year)($0.73) Net Income$-147,340,000.00 Net Margins-46.20% Return on Equity-44.37% Return on Assets-22.05%Miscellaneous Employees298 Outstanding Shares218,214,000Market Cap$5.05 billion OptionableOptionable Array Biopharma (NASDAQ:ARRY) Frequently Asked Questions What is Array Biopharma's stock symbol? Array Biopharma trades on the NASDAQ under the ticker symbol "ARRY." How were Array Biopharma's earnings last quarter? Array Biopharma Inc (NASDAQ:ARRY) posted its quarterly earnings data on Tuesday, February, 5th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.11. The biopharmaceutical company earned $82.55 million during the quarter, compared to analysts' expectations of $52.44 million. Array Biopharma had a negative return on equity of 44.37% and a negative net margin of 46.20%. Array Biopharma's revenue for the quarter was up 95.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.17) earnings per share. View Array Biopharma's Earnings History. When is Array Biopharma's next earnings date? Array Biopharma is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Array Biopharma. What price target have analysts set for ARRY? 9 equities research analysts have issued twelve-month price objectives for Array Biopharma's shares. Their predictions range from $20.00 to $33.00. On average, they expect Array Biopharma's stock price to reach $26.50 in the next year. This suggests a possible upside of 14.6% from the stock's current price. View Analyst Price Targets for Array Biopharma. What is the consensus analysts' recommendation for Array Biopharma? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Array Biopharma in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Array Biopharma. Has Array Biopharma been receiving favorable news coverage? Media headlines about ARRY stock have trended positive this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Array Biopharma earned a news sentiment score of 2.7 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. Who are some of Array Biopharma's key competitors? Some companies that are related to Array Biopharma include Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ) and SAGE Therapeutics (SAGE). Who are Array Biopharma's key executives? Array Biopharma's management team includes the folowing people: Mr. Ron Squarer, CEO & Director (Age 52)Mr. Jason Haddock, Chief Financial Officer (Age 49)Mr. Andrew R. Robbins, Chief Operating Officer (Age 43)Mr. Curtis G. Oltmans, Exec. VP, Gen. Counsel & Sec. (Age 56)Dr. Victor Sandor, Chief Medical Officer (Age 53) Who are Array Biopharma's major shareholders? Array Biopharma's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.77%), Millennium Management LLC (1.37%), Northern Trust Corp (1.18%), Artal Group S.A. (1.15%), Geode Capital Management LLC (1.14%) and Sectoral Asset Management Inc (0.99%). Company insiders that own Array Biopharma stock include Andrew R Robbins, Carrie Smith Cox, Charles M Baum, Curtis Gale Oltmans, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Nicholas A Saccomano, Ron Squarer and Victor Sandor. View Institutional Ownership Trends for Array Biopharma. Which major investors are selling Array Biopharma stock? ARRY stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Millennium Management LLC, Columbus Circle Investors, Canada Pension Plan Investment Board, BlackRock Inc., Two Sigma Advisers LP, Pinnacle Associates Ltd. and Rhenman & Partners Asset Management AB. Company insiders that have sold Array Biopharma company stock in the last year include Andrew R Robbins, Curtis Gale Oltmans, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Nicholas A Saccomano, Ron Squarer and Victor Sandor. View Insider Buying and Selling for Array Biopharma. Which major investors are buying Array Biopharma stock? ARRY stock was bought by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Fiera Capital Corp, Artal Group S.A., Candriam Luxembourg S.C.A., Handelsbanken Fonder AB, New York State Common Retirement Fund, Geode Capital Management LLC and Lisanti Capital Growth LLC. View Insider Buying and Selling for Array Biopharma. How do I buy shares of Array Biopharma? Shares of ARRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Array Biopharma's stock price today? One share of ARRY stock can currently be purchased for approximately $23.13. How big of a company is Array Biopharma? Array Biopharma has a market capitalization of $5.05 billion and generates $173.77 million in revenue each year. The biopharmaceutical company earns $-147,340,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. Array Biopharma employs 298 workers across the globe. What is Array Biopharma's official website? The official website for Array Biopharma is http://www.arraybiopharma.com. How can I contact Array Biopharma? Array Biopharma's mailing address is 3200 Walnut Street, Boulder CO, 80301. The biopharmaceutical company can be reached via phone at 303-381-6600 or via email at [email protected] MarketBeat Community Rating for Array Biopharma (NASDAQ ARRY)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 428 (Vote Outperform)Underperform Votes: 256 (Vote Underperform)Total Votes: 684MarketBeat's community ratings are surveys of what our community members think about Array Biopharma and other stocks. Vote "Outperform" if you believe ARRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARRY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/16/2019 by MarketBeat.com StaffFeatured Article: How do taxes affect a CDs total return?